Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2

被引:259
作者
del Amo, Eva M. [2 ,3 ]
Urtti, Atto [2 ]
Yliperttula, Marjo [1 ]
机构
[1] Univ Helsinki, Fac Pharm, Div Biopharmaceut & Pharmacokinet, FIN-00014 Helsinki, Finland
[2] Univ Helsinki, Ctr Drug Res, FIN-00014 Helsinki, Finland
[3] Univ Kuopio, Dept Pharmaceut, FIN-70211 Kuopio, Finland
关键词
amino acid transport; drug delivery; blood-brain barrier; L-DOPA; drug transport; pharmacokinetics;
D O I
10.1016/j.ejps.2008.06.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
LAT1 and LAT2 are heterodimeric large amino acid transporters that are expressed in various tissues, including the intestinal wall, blood-brain barrier, and kidney. These transporters consist of membrane spanning light chain and heavy chain, and they act as 1:1 exchangers in concert with other amino acid transporters. Only a few drugs (less than 10) are substrates of LAT1 and LAT2, including L-DOPA, alpha-methyldopa, melphalan, and gabapentin. The mechanisms and substrates have been mostly elucidated using mammalian cells and Xenopus oocytes. The in vivo relevance of LAT1 and LAT2 in pharmacokinetics is obscure, because contradictory findings have been reported. It is difficult to make quantitative pharmacokinetic conclusions about LAT1 and LAT2. This is due to the possible involvement of other transporters (including cross-linked heterodimers of light chain with different heavy chains, other overlapping transporters, for example TAT1), competing endogenous amino acids, and saturation phenomena. This review presents the current functional knowledge on LAT1 and LAT2 with emphasis on their potential involvement in pharmacokinetics. (C) 2008 Elsevier B.V All rights reserved.
引用
收藏
页码:161 / 174
页数:14
相关论文
共 84 条
[1]   EFFECT OF PLASMA-LEVELS OF LARGE NEUTRAL AMINO-ACIDS AND DEGREE OF PARKINSONISM ON THE BLOOD-TO-BRAIN TRANSPORT OF LEVODOPA IN NAIVE AND MPTP PARKINSONIAN MONKEYS [J].
ALEXANDER, GM ;
SCHWARTZMAN, RJ ;
GROTHUSEN, JR ;
GORDON, SW .
NEUROLOGY, 1994, 44 (08) :1491-1499
[2]   L-type amino acid transporter-1 expressed in human astrocytomas, U343MGa [J].
Asano, Shinji ;
Kameyama, Megumi ;
Oura, Ayako ;
Morisato, Anna ;
Sakai, Hideki ;
Tabuchi, Yoshiaki ;
Chairoungdua, Arthit ;
Endou, Hitoshi ;
Kanai, Yoshikatsu .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (03) :415-422
[3]   Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters [J].
Babu, E ;
Kanai, Y ;
Chairoungdua, A ;
Kim, DK ;
Iribe, Y ;
Tangtrongsup, S ;
Jutabha, P ;
Li, YW ;
Ahmed, N ;
Sakamoto, S ;
Anzai, N ;
Nagamori, S ;
Endou, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (44) :43838-43845
[4]   LAT1 gene variants -: potential factors influencing the clinical course of phenylketonuria [J].
Bik-Multanowski, Miroslaw ;
Pietrzyk, Jacek J. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 (05) :684-684
[5]   Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport [J].
Boado, RJ ;
Li, JY ;
Wise, P ;
Pardridge, WM .
MOLECULAR GENETICS AND METABOLISM, 2004, 83 (04) :306-311
[6]   Selective expression of the large neutral amino acid transporter at the blood-brain barrier [J].
Boado, RJ ;
Li, JY ;
Nagaya, M ;
Zhang, C ;
Pardridge, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (21) :12079-12084
[7]   Identification of LAT4, a novel amino acid transporter with system L activity [J].
Bodoy, S ;
Martín, L ;
Zorzano, A ;
Palacín, M ;
Estévez, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (12) :12002-12011
[8]  
BOSANQUET AG, 1984, CANCER CHEMOTH PHARM, V12, P183
[9]   Discrimination of two amino acid transport activities in 4F2 heavy expressing Xenopus laevis oocytes [J].
Bröer, A ;
Hamprecht, B ;
Bröer, S .
BIOCHEMICAL JOURNAL, 1998, 333 :549-554
[10]  
CORNFORD EM, 1992, CANCER RES, V52, P138